Clinical Trial Update: A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) [Phase 1]

View source ↗

Summary

A Phase 1 trial update indicates Nanjing Legend Biotech is recruiting for LUCAR-G79D to treat relapsed/refractory systemic lupus erythematosus and idiopathic in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies
• Systemic Lupus Erythematosus

Drugs mentioned

• LUCAR-G79D

Snippet

Sponsor: Nanjing Legend Biotech Co. | Conditions: Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM) | Phase 1 | Status: RECRUITING